title: Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease.
abstract: In phase I (safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our phase I trials, the focus is on phase II (efficacy) trials using gene-marked autologous stem cells.
authors.affiliation: Northwestern University Medical Center, and the Rupert H. Lurie Cancer Center, Chicago, Illinois, USA.
authors.forename: R K
authors.initials: RK
authors.lastname: Burt
authors.forename: M
authors.initials: M
authors.lastname: Brenner
authors.forename: W
authors.initials: W
authors.lastname: Burns
authors.forename: E
authors.initials: E
authors.lastname: Courier
authors.forename: G
authors.initials: G
authors.lastname: Firestein
authors.forename: B
authors.initials: B
authors.lastname: Hahn
authors.forename: H
authors.initials: H
authors.lastname: Heslop
authors.forename: C
authors.initials: C
authors.lastname: Link
authors.forename: H
authors.initials: H
authors.lastname: McFarland
authors.forename: M
authors.initials: M
authors.lastname: Roland
authors.forename: M
authors.initials: M
authors.lastname: Territo
authors.forename: G
authors.initials: G
authors.lastname: Tsokos
authors.forename: A
authors.initials: A
authors.lastname: Traynor
mesh_terms: D001327:Autoimmune Diseases / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005822:Genetic Vectors; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000502:physiology; D006801:Humans; D014182:Transplantation, Autologous